- Revenue: Over $106 billion in Q2 2026, an increase of over 7% year-over-year.
- Adjusted Operating Income: Approximately $5.2 billion, up 35% from the prior year quarter.
- Adjusted EPS: $2.58, a significant increase of over 40% year-over-year.
- Cash Flow from Operations: Year-to-date approximately $10.6 billion.
- Healthcare Benefits Segment Revenue: Over $37 billion, up over 3% year-over-year.
- Medical Membership: Approximately 26 million members, down 700,000 year-over-year.
- Healthcare Benefits Adjusted Operating Income: Approximately $2.4 billion.
- Medical Benefit Ratio (MBR): 87.4%, improved meaningfully from the prior year quarter.
- Health Services Segment Revenue: Nearly $52 billion, an increase of over 11% year-over-year.
- Health Services Adjusted Operating Income: Over $1.7 billion, up 10% year-over-year.
- Pharmacy and Consumer Wellness Segment Revenue: Nearly $34 billion, a slight increase from the prior year quarter.
- Same-Store Pharmacy Sales: Grew approximately 3%.
- Same-Store Prescription Volumes: Increased 7%.
- Same-Store Front Store Sales: Increased 100 basis points versus the prior year quarter.
- Pharmacy and Consumer Wellness Adjusted Operating Income: Nearly $1.5 billion, an increase of over 10% year-over-year.
- Full Year 2026 Adjusted EPS Guidance: Raised to a range of $7.90 to $8.10.
- Full Year 2026 Revenue Guidance: At least $414 billion.
- Full Year 2026 Cash Flow from Operations Guidance: At least $11.5 billion.
Release Date: August 05, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- CVS Health Corp CVS delivered strong second-quarter results with all operating segments growing earnings, generating adjusted EPS of $2.58, a 40% increase year-over-year.
- The company raised its full-year 2026 adjusted EPS guidance by $0.60 to a range of $7.90-$8.10 and increased its cash flow from operations outlook by $2 billion to at least $11.5 billion.
- Aetna's margin recovery is progressing well, with over $2 billion in year-over-year adjusted operating income improvement in the first half of 2026, driven by strong medical cost management and disciplined pricing.
- The Pharmacy and Consumer Wellness segment delivered an exceptional quarter, with same-store prescription volumes up 7% and adjusted operating income up over 10%, driven by core pharmacy strength and contributions from the Rite Aid transaction.
- CVS Health Corp (CVS) is strategically positioning itself in the GLP-1 market through partnerships with Eli Lilly and Novo Nordisk, offering affordable cash-pay options and leveraging its MinuteClinic and pharmacy network to capture growth.
- The company is making significant progress in its technology and AI initiatives, including the launch of its Health 100 platform and AI-powered assistant HIO, which are expected to drive efficiencies and enhance the consumer experience.
Negative Points
- CVS Health Corp (CVS) expects a headwind in 2027 from continued pressure in its 340B business due to manufacturer restrictions and the dynamic environment for the program.
- The company anticipates membership declines in Caremark next year due to a deliberate approach to client renewals and the selling season, as well as product actions and market exits by some health plan customers.
- The transition to net cost price models in the PBM industry, accelerated by recent legislation and regulatory developments, is creating near-term earnings pressure and uncertainty.
- The company is facing challenges from the independent dispute resolution process under the No Surprises Act, which is being abused by a small group of players and is frustrating self-funded employers.
- CVS Health Corp (CVS) is experiencing pressure from pharmacy reimbursement and regulatory-related price reductions on certain drugs, which partially offset revenue growth in its Pharmacy and Consumer Wellness segment.
- The company's 2027 outlook of at least $8.44 in adjusted EPS assumes only offsetting dilution from share repurchases, with no additional capital deployment, limiting potential upside from buybacks.
Q & A Highlights
Q: Can you provide more detail on the preliminary 2027 headwinds and tailwinds, particularly around Health Services, and how you plan to offset the 340B headwinds and Caremark membership declines?
A: CEO David Joyner and CFO Brian Newman highlighted that while 2027 will see headwinds from 340B dynamics and Caremark membership declines due to a disciplined approach to client renewals and health plan market exits, the company remains confident in its mid-teens adjusted EPS CAGR from 2025-2028. They provided a "reasonable floor" for 2027 adjusted EPS of at least $8.44, implying ~13% growth off an adjusted baseline of $7.46. Prem Shah, President of Pharmacy and Consumer Wellness, noted that the specialty pharmacy business, including high generic adherence and innovative solutions like Cordavis (which generated over $1.8 billion in savings on Humira), will help offset these pressures.
Q: What is driving the strong performance in the Health Benefits segment, and how are you thinking about Medicare Advantage and Part D bids for 2027?
A: Steve Nelson, President of Aetna, stated that the segment's strong performance is driven by disciplined pricing, favorable member mix, leading Star scores, and strong medical cost management. For 2027, Aetna is taking the same disciplined approach to bids, assuming continuation of elevated trends, and is well-positioned to make continued progress toward target margins. He also noted that group Medicare Advantage has renewed about 75% of its book for 2027, and Part D is performing in line with expectations after deliberate actions to de-risk and simplify the product portfolio.
Q: Can GLP-1s become a meaningful growth component for CVS, and how is the company capitalizing on this opportunity?
A: CEO David Joyner explained that CVS is capturing GLP-1 volumes in funded programs through Caremark and Aetna while also serving the growing cash-pay market. Prem Shah detailed the company's direct-to-consumer platform, including MinuteClinic's 24/7 virtual weight management offering reduced to $29, and partnerships with Eli Lilly and Novo Nordisk to provide cash-pay pricing for same-day pickup. This multi-pronged approach leverages CVS's 9,000 community pharmacies and positions the company as a leader in affordability, access, and convenience for all FDA-approved GLP-1s.
Q: Is there any share repurchase or other capital deployment assumed in the 2027 EPS floor of $8.44?
A: CFO Brian Newman confirmed that, similar to the Investor Day framework, the 2027 outlook only assumes offsetting dilution and does not include any additional share repurchases. He noted that cash flow is improving, which will allow the company to evaluate capital deployment opportunities as its leverage position improves.
Q: How sustainable is the strong Pharmacy and Consumer Wellness (PCW) growth, and can you update us on the cost-plus rollout and margin stabilization?
A: Prem Shah highlighted the multi-year strategy of fixing store service (now at best NPS levels), empowering pharmacists, and launching CVS Cost Manager (cost-based pricing) to address reimbursement pressure. He noted that script growth remains above market levels, with the Rite Aid transaction providing an incremental tailwind. The company expects to continue growing faster than the market through unique solutions and high service levels, creating incremental operating leverage across its 9,000 stores. Front store sales also grew 100 basis points despite a challenging macro environment.
Q: How is the commercial risk business performing, and what is the impact of the No Surprises Act and independent dispute resolution (IDR) process on cost trends?
A: Steve Nelson stated that the commercial business is a strong performer, in line with expectations, with strong growth in both fully insured and self-insured segments due to innovative products and technology. Regarding IDR, he acknowledged it is a component of trend that is being watched and accounted for, but noted the dispute resolution process is "clearly being abused by a small group of players." Aetna is working upstream with providers to bring them into networks at reasonable rates and is looking forward to working with regulators to resolve the issue, as self-funded employers are frustrated with the process.
Q: What is the timing and magnitude of technology and AI investments, and how will they drive cost savings and revenue opportunities?
A: CEO David Joyner emphasized a shift toward becoming a "consumer-based healthcare technology business" with a $20+ billion investment commitment over the next decade. Steve Nelson highlighted four deployment areas: efficient claims processing, improved colleague experience (reducing case prep time from 90 minutes to 2 minutes), enhanced member experience, and reimagined provider interactions (83% of prior authorizations approved in real time). Prem Shah added that AI is improving clinical quality and reducing pharmacist burden, freeing up a million hours for patient care. CFO Brian Newman noted over $1 billion in OpEx savings already generated through these efforts.
Q: What is driving the incremental 340B pressure, and how is it being offset within Health Services this year?
A: Prem Shah explained that the 340B program is facing a dynamic environment as pharmaceutical manufacturers impose restrictions on covered entities, which impacted Q2 results. This was fully offset by broader Caremark outperformance, including higher specialty generic penetration rates. He also noted that as large specialty drugs become generic, it creates additional pressure. CFO Brian Newman reiterated confidence in the full-year Health Services outlook, with 340B expected to be a headwind in 2027, but the company has multiple paths to deliver on its commitments.
Q: Can you elaborate on the value creation activities pulled forward in the first half of the year, and does this create space for additional opportunities in the back half?
A: CFO Brian Newman explained that investments in capabilities and technology continue across business segments, with some costs appearing in the corporate segment in Q2. He stated that the company feels confident about where it is investing dollars and tracking returns, with these investments captured in the full-year guidance raise and the 2027 floor. CEO David Joyner added that the company is balancing technology investments between efficiency/productivity gains and growth-oriented initiatives, such as the Health 100 platform, which is showing early signs of success.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
